PRAECIS PHARMACEUTICALS INCORPORATED To Announce Fourth Quarter and Ye

    Business Editors

    WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 21, 2005--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ:PRCS), today announced that it will report fourth quarter and year-end 2004 financial results on Friday, January 28, 2005, before the financial markets open. The release will be followed by a conference call at 9:00 a.m., EST, with the investment community and members of PRAECIS' senior management team.
    The Company's conference call may be accessed live by visiting PRAECIS' website at http://www.praecis.com under "Investors" and "Webcast Live." Interested parties also may listen to a replay of the call beginning Friday, January 28, at 12:00 Noon (EST), until midnight Friday, February 4, by calling 888-203-1112, or 719-457-0820, and entering the passcode 719969.
    PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies to address significant unmet medical needs. PRAECIS has received approval from the FDA to market Plenaxis(R) (abarelix for injectable suspension) in the United States. PRAECIS employed its proprietary LEAP(TM) (Ligand Evolution to Active Pharmaceuticals) technology in the development of Plenaxis(R). PRAECIS also has an innovative product pipeline, including clinical programs in Alzheimer's disease and non-Hodgkin's lymphoma, as well as discovery programs in oncology and inflammation therapies.

--30--CE/cg*

CONTACT: PRAECIS PHARMACEUTICALS INCORPORATED Edward C. English (Investor), 781-795-4320 ted.english@praecis.com.

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: PRAECIS PHARMACEUTICALS INCORPORATED

Copyright Business Wire 2005